Masimo Corporation
Masimo Reports Strong Second Quarter 2025 Financial Results
Summary
Masimo Corporation reported 8% growth in GAAP revenue to $371 million and 7% growth in non-GAAP revenue to $370 million for the second quarter of 2025. The company also reported non-GAAP net income per diluted share of $1.33, a 46% increase from the prior year period. The company announced updated guidance for the full year 2025, excluding the impact of new tariffs, with non-GAAP revenue expected to be between $1,505 million and $1,535 million, an increase of 8% to 11% on a constant currency basis.
Profitelligence Alerts
Get alerts for MASI
Be first to know when Masimo Corporation files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Masimo Corporation
Masimo Corporation is a global leader in noninvasive monitoring technologies, specifically focusing on developing innovative medical devices that improve patient outcomes and reduce the cost of care. The company's flagship product line includes advanced signal processing pulse oximetry devices, which are pivotal in accurately measuring oxygen levels, pulse rate, and other vital signals without the need for invasive procedures. Masimo's technology is widely adopted across various healthcare settings including hospitals, outpatient treatment centers, and alternative care sites, enhancing patient monitoring and aiding clinicians in detecting potential health issues more efficiently. Besides, Masimo’s products are recognized for their precision and reliability, demonstrating robustness even in challenging clinical environments where motion and low perfusion can affect monitoring accuracy. The corporation is committed to expanding its technological suite, covering a spectrum of health monitoring solutions that contribute to improved healthcare practices globally. Based in Irvine, California, Masimo's ongoing innovation continues to set benchmarks in the healthcare industry, influencing a wide range of sectors from emergency care to surgical and critical care monitoring.
Official SEC Documents
Advertisement